76290-78-3
Chemical Structure
6-Sulfatoxymelatonin sodium
- CAS No.: 76290-78-3
- Formula:C13H15N2NaO6S
- Molecular Weight:350.32
IUPAC Name: (R)-5-(((2S,3S)-1-(((3S,6R,9S,12R,15S,18R,21S)-9-((1H-imidazol-5-yl)methyl)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-((S)-sec-butyl)-6-(carboxymethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl)amino)-3-methyl-1-oxopentan-2-yl)amino)-4-((S)-2-((R)-2-((1S,2S)-1-amino-2-methylbutyl)-4,5-dihydrothiazole-4-carboxamido)-4-methylpentanamido)-5-oxopentanoic acid
InChIKey: RRAMWSGKMQYWPL-UHFFFAOYSA-M
SMILES: CC(NCCC1=CNC2=C1C=C(OC)C(OS(=O)(O[Na])=O)=C2)=O
Biological Activity: 6-Sulfatoxymelatonin sodium is a metabolite of Melatonin (HY-B0075) and serves as a detection marker for Melatonin. 6-Sulfatoxymelatonin sodium shows a decreasing trend with increasing age, and its urinary excretion is closely correlated with plasma Melatonin levels, which can reflect changes in the secretion phase of melatonin. 6-Sulfatoxymelatonin sodium is associated with reduced risks of diabetic retinopathy and coronary heart disease, and can act as a biomarker for microvascular and macrovascular complications of type 2 diabetes mellitus. 6-Sulfatoxymelatonin sodium can be used in studies related to type 2 diabetes mellitus and coronary heart disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
6-Sulfatoxymelatonin sodium | 6-Sulfatoxymelatonin sodium is a metabolite of Melatonin (HY-B0075) and serves as a detection marker for Melatonin. 6-Sulfatoxymelatonin sodium shows a decreasing trend with increasing age, and its urinary excretion is closely correlated with plasma Melatonin levels, which can reflect changes in the secretion phase of melatonin. 6-Sulfatoxymelatonin sodium is associated with reduced risks of diabetic retinopathy and coronary heart disease, and can act as a biomarker for microvascular and macrovascular complications of type 2 diabetes mellitus. 6-Sulfatoxymelatonin sodium can be used in studies related to type 2 diabetes mellitus and coronary heart disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
6-Sulfatoxymelatonin-d4 sodium | 99.18% | 6-Sulfatoxymelatonin-d4 sodium is the deuterated-labeled 6-Sulfatoxymelatonin sodium (HY-W587817). 6-Sulfatoxymelatonin sodium is a metabolite of Melatonin (HY-B0075) and serves as a detection marker for Melatonin. 6-Sulfatoxymelatonin sodium shows a decreasing trend with increasing age, and its urinary excretion is closely correlated with plasma Melatonin levels, which can reflect changes in the secretion phase of melatonin. 6-Sulfatoxymelatonin sodium is associated with reduced risks of diabetic retinopathy and coronary heart disease, and can act as a biomarker for microvascular and macrovascular complications of type 2 diabetes mellitus. 6-Sulfatoxymelatonin sodium can be used in studies related to type 2 diabetes mellitus and coronary heart disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zheng Y, et al. Melatonin alleviates vascular endothelial cell damage by regulating an autophagy-apoptosis axis in Kawasaki disease. Cell proliferation. 2022 Jun;55(6):e13251.
- [2]. Tanaka K, et al. Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes. Journal of diabetes investigation. 2021 Apr;12(4):601-609.
- [3]. van Faassen M, et al. Mass spectrometric quantification of urinary 6-sulfatoxymelatonin: age-dependent excretion and biological variation. Clinical chemistry and laboratory medicine. 2020 Jul 16;59(1):187-195.
- [4]. Bojkowski CJ, et al. Factors influencing urinary 6-sulphatoxymelatonin, a major melatonin metabolite, in normal human subjects. Clinical endocrinology. 1990 Oct;33(4):435-44.
